Malmstrom, A. Et Al. 2012. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. LANCET ONCOLOGY , vol.13, no.9 , 916-926.

Malmstrom, A., Gronberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., ... ABACIOGLU, M. U.(2012). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. LANCET ONCOLOGY , vol.13, no.9, 916-926.

Malmstrom, Annika Et Al. "Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial," LANCET ONCOLOGY , vol.13, no.9, 916-926, 2012

Malmstrom, Annika Et Al. "Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial." LANCET ONCOLOGY , vol.13, no.9, pp.916-926, 2012

Malmstrom, A. Et Al. (2012) . "Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial." LANCET ONCOLOGY , vol.13, no.9, pp.916-926.

@article{article, author={Annika Malmstrom Et Al. }, title={Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial}, journal={LANCET ONCOLOGY}, year=2012, pages={916-926} }